Drug details:
Molecular formula: C₂₉H₃₃N₉

Standard name: (5R,6R)-5,6-bis[[4-(2-phenylethyl)triazol-1-yl]methyl]-4,5,6,7-tetrahydro-1H-benzimidazol-2-amine

Curated SMILES: NC1=NC2=C(C[C@@H](CN3C=C(CCC4=CC=CC=C4)N=N3)[C@H](CN3C=C(CCC4=CC=CC=C4)N=N3)C2)N1

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: In vitro
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.

Pseudomonas
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: In vitro
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.

Staphylococcus
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: In vitro
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.